References
- Pawarode A, Shukla S, Minderman H, et al. Differential effects of the immunosuppressive agents cyclosporine A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother Pharmacol 2007; 60: 179–188
- Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 4: 525–537
- Arceci R J, Stieglitz K, Biere B E. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992; 80: 1528–1536
- Shang S, Seedhouse C, Russell N, Pallis M. Low dose rapamycin does not modulate p-glycoprotein function in acute myeloid leukemia. Leuk Res 2008; 32: 836–837
- Shor B, Ahang W G, Toral-Barza L, et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008; 68: 2934–2943
- Guertin D A, Sabatini D M. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9–22
- Pop I, Pop L, Vitetta E S, Ghetie M A. Generation of multidrug resistant lymphoma cell lines which stably express P-glycoprotein. Oncol Rep 2008; 19: 889–895
- Ghetie M A, Richardson J, Tucker T, et al. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer 1990; 45: 481–485
- Han Z, Hong L, Han Y, et al. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 2007; 26: 261–268
- Tam K A, Yang Z F, Lau C K, et al. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 2009; 273: 201–209